NAMSA Announces Intent to Acquire Contract Research Organization, ÅKRN
NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its intent to acquire ÅKRN Scientific Consulting, a prominent European Medical Device CRO based in Madrid, Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220321005062/en/
ÅKRN, founded in 2018, focuses on providing exceptional clinical and regulatory services to the medical device and diagnostic industries in Europe. Grounded in medicine and science, the organization assists Sponsors move MedTech products from medical discovery into clinical development, commercialization and Post-Market Follow-Up. Known for their expertise in Cardiovascular research, ÅKRN’s Team of Clinical Scientists and Project Managers serve as trusted Client Advisors throughout the complete clinical development process via diligent planning and superior execution.
“We are thrilled to welcome ÅKRN to NAMSA,” said Dr. Christophe Berthoux, CEO of NAMSA. “The organization is well-respected for their proficiency in European medical device regulations and providing exceptional clinical support to MedTech Sponsors. Adding them to our team will expand our depth of expertise, enabling us to meet the growing demand for safe, efficient clinical development and commercialization of life-changing medical products,” Dr. Berthoux concluded.
As the global leader in the medical device testing industry since 1967, NAMSA also provides Sponsors support in the areas of regulatory, reimbursement, quality, and clinical research services. NAMSA’s full continuum development services helps Clients overcome development hurdles, mitigate concerns and streamline commercialization efforts. Through proactive planning of varying global regulatory requirements and clinical research obligations, NAMSA’s services are proven to accelerate time-to-market and lower development costs up to 50 percent over industry averages.
“ÅKRN is a wonderful partner for NAMSA—I feel we have a perfect fit surrounding company values and a team that shares the same drive to provide exceptional service and resources to the medical device and diagnostic industries,” commented Dr. Maria Nyåkern, ÅKRN CEO. “Our team, strongly grounded in medicine and science, looks forward to partnering with NAMSA as we continue to increase our presence globally and in Europe. With the expanded expertise of our combined organizations, we will serve as the world’s leading CRO for Cardiovascular research services,” Dr. Nyåkern concluded.
The acquisition of ÅKRN increases NAMSA’s global scale, now serving MedTech Clients across 19 locations throughout APAC, Europe, North America and South America.
The price and terms of the intended transaction are undisclosed.
ABOUT NAMSA
Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes.
Web: namsa.com
ABOUT AKRN
Grounded in medicine and science, ÅKRN helps Sponsors move from medical discovery into clinical development, commercialization, and Post-Market Follow-Up. ÅKRN offers optimized regulatory and clinical services tailored to MedTech Clients and Partners in a cost-conscious and diligent manner. ÅKRN’s experience covers many medical device therapeutic areas, including cardiovascular devices and In Vitro Diagnostics (IVD).
Web: akrnconsulting.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005062/en/
Contact information
NAMSA Media Contact
Leah A. Davidson, MA, MBA, PCM
Sr. Manager, Global Marketing Communications
Email: ldavidson@namsa.com
AKRN Media Contact
Maria Nyåkern, MSc, PhD
Chief Executive Officer
Email: maria.nyakern@akrnconsulting.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom